Clinical Trial Update: Long Term Safety Study of Levalbuterol and Racemic Albuterol in Subjects Twelve Years of Age and Older With Asthma [Phase 3]

View source ↗

Summary

A Phase 3 long-term safety study evaluated levalbuterol and racemic albuterol in subjects 12 years of age and older with asthma. The trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Albuterol (racemic) (albuterol)
• Xopenex (Levalbuterol)

Snippet

Sponsor: Sumitomo Pharma America, Inc. | Conditions: Asthma | Phase 3 | Status: COMPLETED